Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Becton Dickinson and Co    BDX

News SummaryMost relevantAll newsSector newsTweets

Becton Dickinson's 1st-Quarter Earnings Surge; Raises Year-View

share with twitter share with LinkedIn share with facebook
share via e-mail
02/05/2013 | 12:50pm CEST
   By Saabira Chaudhuri 

Becton Dickinson & Co.'s (>> Becton, Dickinson and Co.) fiscal first-quarter earnings more than doubled as the medical device maker recorded revenue growth across all its segments, while margins also widened.

For the current year, Becton raised the bottom end of its revenue guidance, now expecting foreign currency neutral revenue growth starting at 4% versus its prior view starting at 3.5%. It now expects per-share earnings from continuing operations between $5.69 and $5.72, up from its prior view of earnings between $5.58 and $5.64.

The maker of products like surgical blades and test kits last spring struck a deal to sell the bulk of its lab-products business to Corning Inc. (>> Corning Incorporated) for $730 million in cash. Analysts who follow the company noted the sale stripped Becton Dickinson of a cash cow yet also gave it the freedom to focus on businesses with higher growth potential.

Ahead of the company's earnings announcement, analysts at Mizuho Securities downgraded Becton's ratings, noting that the company's life science research business--which makes up about 15% of sales--has been a drag on results for the past year, adding that they see no significant catalysts for the business in the near-term, as the academic market continues to be sluggish.

Still, Chief Executive Vincent A. Forlenza on Tuesday said the company is "starting to see notable results," adding that Becton is "growing revenues across our three segments, driving margin expansion and delivering a higher quality of earnings."

For the quarter ended Dec. 31, Becton Dickinson reported a profit of $625.4 million, or $3.13 a share, compared with $263 million, or $1.21 a share, a year earlier. Per-share earnings from continuing operations were $1.35 versus $1.14.

Revenue increased 3.7% to $1.9 billion. Analysts polled by Thomson Reuters most recently forecast earnings of $1.24 a share on revenue of $1.86 billion.

Gross margin widened to 52.9% from 50.8%.

Becton Dickinson's sales grew 3% in the U.S. and 4.3% internationally. The company's medical unit, its largest by revenue, reported sales rose 3.5%. The diagnostics business posted revenue growth 5%, while bioscience revenue was up 1.7%.

Shares closed Monday at $85.16 and were inactive premarket. The stock has risen 11% in the past three months.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Becton, Dickinson and Co., Corning Incorporated
share with twitter share with LinkedIn share with facebook
share via e-mail
10/13 World Molecular Diagnostics Market is Projected to Reach More Than US$ 30 Bil..
10/06 BECTON DICKINSON AND : Technical Reports on Medical Supplies Equities -- Baxter,..
10/05 BECTON DICKINSON AND : BD Announces Live Webcast of Fourth Fiscal Quarter Earnin..
10/02 BECTON DICKINSON AND : $30,272 Federal Contract Awarded to Becton Dickinson & Co..
10/02 BECTON, DICKINSON AND COMPANY (NYSE : BDX) Files An 8-K Departure of Directors o..
09/29 BECTON DICKINSON & CO : Change in Directors or Principal Officers (form 8-K)
09/29 BECTON DICKINSON AND : Timothy M. Ring and David F. Melcher to Join BD Board of ..
09/28 BECTON DICKINSON AND : BD and Euroclone Announce Development and Global Distribu..
09/28 BECTON DICKINSON AND : Federal Contracts Awarded by Federal Agencies in Louisian..
09/28 BECTON DICKINSON AND : BD Introduces New 6mm Pen Needle for Injection Pens
More news
News from SeekingAlpha
10/15 DIVIDEND INCOME UPDATE : September 2017
10/12 My Dividend Growth Portfolio - Q3 2017 Summary
10/12 The Lower Volatility Stock Portfolio For Retirees And Others
10/09 My 86 Stock Portfolio Review- Q3 Dividends UP 16.8% From 2016
10/08 MY K.I.S.S. DIVIDEND PORTFOLIO : 3rd Quarter 2017 Update
Financials ($)
Sales 2017 12 068 M
EBIT 2017 2 819 M
Net income 2017 1 169 M
Debt 2017 6 581 M
Yield 2017 1,41%
P/E ratio 2017 34,39
P/E ratio 2018 25,16
EV / Sales 2017 4,33x
EV / Sales 2018 4,05x
Capitalization 45 700 M
Duration : Period :
Becton Dickinson and Co Technical Analysis Chart | BDX | US0758871091 | 4-Traders
Technical analysis trends BECTON DICKINSON AND CO
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 219 $
Spread / Average Target 9,1%
EPS Revisions
Vincent A. Forlenza Chairman & Chief Executive Officer
Thomas Polen President
Christopher R. Reidy EVP, Chief Financial & Administrative Officer
Ellen R. Strahlman Chief Medical Officer, EVP-Research & Development
Richard Pierle Chief Information Officer & Executive VP
Sector and Competitors